| Study ID | Study follow‐up (months) | BBIBP‐CorV (n) | Adjuvant (n) | Critical outcomes | ||||||
| Confirmed SARS‐CoV‐2 infection after complete vaccination | Confirmed symptomatic COVID‐19 after complete vaccination | Severe or critical COVID‐19 | All‐cause mortality | Systemic reactogenicity events | Any AE | SAE | ||||
| Xia 2020 (ChiCTR2000032459) | 0.92 | 84 | 28 | * | * | * | * | ✓ | ✓ | ✓ |
| Al Kaabi 2021 (NCT04510207; ChiCTR2000034780) | 5 | 13,470 | 13,471 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Xia 2021 (ChiCTR2000032459) | 2.9 | 252 | 252 | * | * | * | * | ✓ | ✓ | * |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.